Albanian patients faced about 11.3 million lek in additional costs for medicines due to the lack of contracting the first reimbursable alternatives during 2025. According to the Supreme State Audit, the second alternative was used for 24 medicines, while the audit identified broader problems with the list of reimbursable medicines, including 200 medicines without contracts and hundreds more without reported consumption.
According to the KLSH report on the implementation of the 2025 budget, for 24 medicines, the lack of contracting the first alternatives has led to the use of secondary alternatives, creating an additional cost for patients, estimated at around 11.3 million lek. This means that the contracting problems have not remained only at the administrative level but have had a direct financial impact on citizens who receive medicines through the reimbursement scheme.
From the verification of reimbursement lists, a total of 200 medicines without contracts were found, of which 64 showed reported consumption and reimbursement payments. For the only and first reimbursed alternatives without the respective contracts, the reimbursement value reached around 10.13 million lek.
Likewise, their availability on the market remains a problem. The Supreme State Audit (KLSH) has identified 373 medicines without reported consumption, including 77 initial alternatives, for which no documented analyses or verifications have been found regarding the causes of the lack of consumption. The audit emphasizes that it has not been sufficiently checked whether these medicines were actually available on the market.

366 million lek unused funds, penalties not applied
Problems with drug administration have been identified at a time when the funds planned for reimbursement have not been fully spent. During 2025, expenses for reimbursing medicines and equipment increased by 2.9% compared to 2024, but the realization reached only 97.1% of the annual plan.
As a result, 366 million lek remain unused, while the audit finds additional costs for patients and deficiencies in drug contracting.

The Supreme State Audit has also found deficiencies in inspections of pharmaceutical warehouses and in the verification of medicine supply. Despite the reported problems, only three thematic inspections have been carried out, and their planning was not based on a documented risk analysis.
Deficiencies in coordination between institutions and in fulfilling contractual obligations have also been accompanied by the non-application of penalties calculated at 42 million lek. Also, the controls of the Mandatory Health Care Insurance Fund did not include all doctors who were found to have exceeded the established reimbursement threshold./ekofin.al
